HSBC Holdings’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $888K | Sell |
4,900
-10,500
| -68% | -$1.93M | ﹤0.01% | 1933 |
|
|
2025
Q4 | $2.72M | Buy |
+15,400
| New | +$2.52M | ﹤0.01% | 1447 |
|
|
2024
Q4 | – | Sell |
-900
| Closed | -$174K | – | 3098 |
|
|
2024
Q3 | $174K | Hold |
900
| – | – | ﹤0.01% | 2669 |
|
|
2024
Q2 | $208K | Sell |
900
-3,600
| -80% | -$782K | ﹤0.01% | 2530 |
|
|
2024
Q1 | $970K | Sell |
4,500
-5,400
| -55% | -$1.26M | ﹤0.01% | 1790 |
|
|
2023
Q4 | $2.56M | Sell |
9,900
-4,000
| -29% | -$982K | ﹤0.01% | 1393 |
|
|
2023
Q3 | $3.58M | Sell |
13,900
-1,200
| -8% | -$321K | ﹤0.01% | 1212 |
|
|
2023
Q2 | $4.28M | Buy |
15,100
+11,400
| +308% | +$3.39M | ﹤0.01% | 1118 |
|
|
2023
Q1 | $1.03M | Sell |
3,700
-12,000
| -76% | -$3.32M | ﹤0.01% | 1750 |
|
|
2022
Q4 | $4.28M | Buy |
15,700
+5,500
| +54% | +$1.55M | ﹤0.01% | 1323 |
|
|
2022
Q3 | $2.75M | Buy |
+10,200
| New | +$2.17M | ﹤0.01% | 1417 |
|
|
2022
Q2 | – | Sell |
-1,600
| Closed | -$337K | – | 3245 |
|
|
2022
Q1 | $337K | Sell |
1,600
-900
| -36% | -$196K | ﹤0.01% | 2677 |
|
|
2021
Q4 | $600K | Buy |
2,500
+1,000
| +67% | +$257K | ﹤0.01% | 2344 |
|
|
2021
Q3 | $424K | Hold |
1,500
| – | – | ﹤0.01% | 2354 |
|
|
2021
Q2 | $519K | Buy |
+1,500
| New | +$454K | ﹤0.01% | 2142 |
|
|
2020
Q4 | – | Sell |
-1,000
| Closed | -$284K | – | 3036 |
|
|
2020
Q3 | $284K | Buy |
+1,000
| New | +$279K | ﹤0.01% | 2285 |
|
|
2020
Q2 | – | Sell |
-2,800
| Closed | -$872K | – | 2658 |
|
|
2020
Q1 | $872K | Sell |
2,800
-85,100
| -97% | -$25.8M | ﹤0.01% | 1523 |
|
|
2019
Q4 | $26M | Sell |
87,900
-37,900
| -30% | -$10.5M | 0.05% | 430 |
|
|
2019
Q3 | $29.3M | Buy |
125,800
+200
| +0.2% | +$46.6K | 0.05% | 378 |
|
|
2019
Q2 | $29.4M | Sell |
125,600
-22,900
| -15% | -$5.29M | 0.06% | 367 |
|
|
2019
Q1 | $35.1M | Buy |
148,500
+12,500
| +9% | +$3.94M | 0.06% | 305 |
|
|
2018
Q4 | $40.9M | Buy |
136,000
+25,100
| +23% | +$8.01M | 0.08% | 265 |
|
|
2018
Q3 | $39.2M | Buy |
110,900
+69,400
| +167% | +$23.9M | 0.06% | 312 |
|
|
2018
Q2 | $12M | Hold |
41,500
| – | – | 0.02% | 722 |
|
|
2018
Q1 | $11.4M | Buy |
+41,500
| New | +$12.9M | 0.02% | 772 |
|
|
2017
Q4 | – | Sell |
-9,473
| Closed | -$2.97M | – | 2064 |
|
|
2017
Q3 | $2.97M | Buy |
+9,473
| New | +$2.81M | ﹤0.01% | 1194 |
|
|
2017
Q2 | – | Sell |
-5,000
| Closed | -$1.37M | – | 2189 |
|
|
2017
Q1 | $1.37M | Sell |
5,000
-29,900
| -86% | -$8.45M | ﹤0.01% | 1336 |
|
|
2016
Q4 | $9.9M | Sell |
34,900
-6,300
| -15% | -$1.87M | 0.02% | 723 |
|
|
2016
Q3 | $12.9M | Buy |
41,200
+9,000
| +28% | +$2.67M | 0.03% | 582 |
|
|
2016
Q2 | $7.79M | Sell |
32,200
-4,800
| -13% | -$1.27M | 0.02% | 749 |
|
|
2016
Q1 | $9.63M | Sell |
37,000
-28,700
| -44% | -$7.58M | 0.03% | 656 |
|
|
2015
Q4 | $20.1M | Buy |
65,700
+61,200
| +1,360% | +$17.6M | 0.05% | 445 |
|
|
2015
Q3 | $1.31M | Buy |
4,500
+1,324
| +42% | +$437K | ﹤0.01% | 1164 |
|
|
2015
Q2 | $1.28M | Sell |
3,176
-26,124
| -89% | -$10.5M | ﹤0.01% | 1183 |
|
|
2015
Q1 | $12.4M | Sell |
29,300
-3,300
| -10% | -$1.3M | 0.02% | 593 |
|
|
2014
Q4 | $11.1M | Buy |
32,600
+8,900
| +38% | +$2.88M | 0.02% | 631 |
|
|
2014
Q3 | $7.84M | Buy |
23,700
+22,600
| +2,055% | +$7.45M | 0.02% | 733 |
|
|
2014
Q2 | $347K | Hold |
1,100
| – | – | ﹤0.01% | 1567 |
|
|
2014
Q1 | $336K | Buy |
+1,100
| New | +$349K | ﹤0.01% | 1506 |
|
Other funds holding BIIB
VCM
VPM
HSBC Holdings's BIIB Position: Q1 2026 in Review
HSBC Holdings reduced its Biogen (BIIB) stake by 8% in Q1 2026, selling an estimated $7.4M and leaving 463,652 shares worth $84.6M. The position accounts for 0.04% of the portfolio, ranked #378.
HSBC Holdings first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $166M in Q1 2015. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- HSBC Holdings held 463,652 shares of Biogen worth $84.6M as of Q1 2026.
- HSBC Holdings sold 40,180 Biogen shares in Q1 2026, an estimated $7.4M.
- Biogen made up 0.04% of HSBC Holdings's portfolio in Q1 2026, its #378 holding.
- HSBC Holdings first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- HSBC Holdings's Biogen position peaked at $166M in Q1 2015.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.